Navigation Links
Emergency response and nanotechnology
Date:7/14/2008

Learning from Past Emergency Response

In a special session running all day Wednesday, presenters will share lessons learned during past incidents involving emergency evacuations, including some involving radiation releases, and the ensuing emergency response (some involving radiation). Presenters use these lessons to model future event responses. One such paper ("Assessment of Emergency Response Planning and Implementation in the Aftermath of Major Natural Disasters and Technological Accidents", Patricia Milligan, pxm@nrc.gov) highlights what has been learned about emergency evacuations: "An important countermeasure in all radiological emergency response plans in the United States is the evacuation of the population in the event of a general emergency condition at a nuclear power plant. In January 2005, the U.S. Nuclear Regulatory Commission (NRC) published its landmark report, "Identification and Analysis of Factors Affecting Emergency Evacuations" (NUREG/CR 6864/), which remains the most comprehensive investigation of public evacuations in the United States in more than 15 years. Data was collected for 230 evacuation incidents, occurring between January 1, 1990 and June 30, 2003. Detailed case studies were prepared for a subset of 50 incidents that were selected based on a profiling and ranking scheme designed to identify evacuation incidents of sufficient complexity to challenge the local and regional emergency response capabilities.

Other highlights in emergency response session:

  • Evacuation or shelter-in-place (Wednesday, 8:45 a.m.)
  • Effectively using measures to mitigate the health effects of radiation exposure (Thursday, 8:45 a.m.)
  • Current capabilities versus what may be needed in a response effort (Wednesday, 9:45 a.m.)
  • Protection of life and property after a radiological dispersal device is activated (Wednesday, 11:45 a.m.)

The Future of Nanotechnology

Beginning at 4:00 p.m. Wednesday afternoon, nanotechnology will be highlighted in a series of presentations designed to increase awareness of new opportunities and challenges. Leading the session will be individuals from Health International Inc. discussing the increased use of nanoparticles having a global exponential impact and revolutionizing nearly every industry: agricultural, chemical, biological, pharmaceutical, medical, electronic, green-energy. This use, however, may pose a health risk for workers and consumers. Nanoscale materials are virtually invisible, yet once inhaled or ingested are able to penetrate and leave deposits on the cell walls of living organs and tissues undetected. Tools and solutions for assessing nanotech and nanoscale materials could be implemented easily based on existing models and methodologies that take into account the delicate balance between security and safety.

Other highlights in the nanotechnology session:

  • The National Institute for Occupational Safety and Health safety plan for working with nanoparticles (Wednesday, 4:15 p.m.)
  • Potential use of nanoparticles as radiopharmaceuticals (Wednesday, 4:30 p.m.)
  • Panel discussion on nanotechnology (Wednesday beginning at 4:45 p.m.)


'/>"/>

Contact: Kelly Classic
media@hps.org
507-254-8444
Health Physics Society
Source:Eurekalert

Related biology news :

1. NASA responds to California wildfire emergency imaging request
2. Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling
3. Triage study challenges notions of emergency medical response to disaster
4. Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer
5. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
6. Yale scientists create artificial cells that boost the immune response to cancer
7. Positron emission tomography superior to standard evaluation tools in measuring treatment response
8. Nonlinear ecosystem response points to environmental solutions
9. Scientists discover a new player in innate immune response
10. Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity
11. 2 genes are important key to regulating immune response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, ... essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the company's ... is a small, thin, SODIMM-style module that fits a standard 204-pin SODIMM socket ...
(Date:12/8/2016)... Maryland (PRWEB) , ... December ... ... announces the commercial launch of flexible packaging for their exceptionally efficient ... disposable bag system extends RoosterBio’s portfolio of bioprocess media products engineered to ...
(Date:12/8/2016)... 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), ... and plans to commercialize innovative therapeutics for patients ... stock were approved for trading on the OTCQX ... the OTCQX, effective today, under the ticker symbol ... market, companies must meet high financial standards, follow ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
Breaking Biology Technology: